Patients with estrogen receptor-positive breast cancer account for most of breast cancer patients, while patients with estrogen receptor-positive breast cancer have a poor prognosis and are prone to tamoxifen resistance (13, 14). This evidence concerns the gene ESR1 and breast carcinoma.